Around the beginning of May 2018 Delphi Medical were made aware of the potential risk of cost increases in buprenorphine secondary to the implementation of a central pricing control mechanism.
The most important issue from a Delphi Medical point of view is to ensure that our patients receiving buprenorphine have continuity of care as part of their treatment plans, and that new patients coming into our service have the option of buprenorphine as part of their individualised treatment journey. The importance of subjective confidence in treatment for opioid dependence cannot be underestimated.
Therefore, the option of not prescribing buprenorphine due to cost is not an option that Delphi Medical will take.
